Skip to main content
LLY
NYSE Life Sciences

Foundayo Cuts Sleep Apnea Events ~44%, Lilly Plans Year-End FDA Filing

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1,394.15
Mkt Cap
$1.312T
52W Low
$850.51
52W High
$1,453
52W Position info
64% above low
Off High info
4.1% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

LLY sits 64% above its 52-week low of $850.51 on light trading volume (0.2× avg).

Summary

Foundayo (orforglipron), Lilly's oral GLP-1, hit its primary endpoint in a late-stage obstructive sleep apnea program, cutting breathing interruptions by about 44% in patients not on PAP therapy and nearly 28% in those using it. At 52 weeks, roughly 32% of non-PAP patients and nearly 20% of PAP users reached remission or mild disease, with side effects consistent with prior trials (mostly mild-to-moderate GI). Lilly will file for the sleep apnea indication with the FDA by year-end, opening a label expansion beyond obesity for a drug that already showed cardiovascular benefit in ACHIEVE-4 in September. Shares rose 3.1% to $1,396.02, near the 52-week high of $1,453, on a stock that has already run hard through Q3's 39% revenue growth and the retatrutide head-to-head win over Ozempic. The sleep apnea label would add a large, under-treated population with clear cardiovascular overlap — incremental revenue on top of the obesity franchise rather than a new pipeline bet. Watch the FDA submission by year-end and any subsequent review timeline.

At the time of this announcement, LLY was trading at $1,394.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 06, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,346.00
Real-time Price: $1,396.40 info
Change: +$50.40 (+4%) info
Market Cap: $1.313T info
LLY
Nov 04, 2026, 1:53 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,416.54
Real-time Price: $1,396.40 info
Change: -$20.14 (-1%) info
Market Cap: $1.313T info
LLY
Oct 29, 2026, 3:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1,368.10
Real-time Price: $1,396.40 info
Change: +$28.30 (+2%) info
Market Cap: $1.313T info
LLY
Oct 29, 2026, 12:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,370.30
Real-time Price: $1,396.40 info
Change: +$26.10 (+2%) info
Market Cap: $1.313T info
LLY
Oct 29, 2026, 11:35 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1,363.50
Real-time Price: $1,396.40 info
Change: +$32.90 (+2%) info
Market Cap: $1.313T info